News

Zacks Investment Research on MSN1d
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...
Regeneron Expands Clinical-Stage Obesity Portfolio With Strategic In-Licensing Of Novel Dual GLP-1/GIP Receptor Agonist
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...
Seeking Alpha2d
REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...
Pharmaceutical Technology on MSN4d
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
pharmaphorum2d
BioNTech cancer vaccine hits the spot in melanoma
The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in 184 patients with advanced melanoma who have relapsed after or not responded to treatment ...